GlassScriptPhysician profile
Melissa Johnson
NPI 1255896338
$6,384.03
in general payments reported to CMS, 2019-2025
33 companies · $2,096 in 2025
The $2,096 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $443 · 2023: $1,105 · 2024: $2,210 · 2025: $2,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,411.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,054.47 | 2021-2025 | |
| Biogen, INC. | $679.59 | 2024-2025 | Vumerity, Tysabri, Leqembi |
| Pfizer INC. | $413.44 | 2023-2025 | |
| Lundbeck LLC | $193.80 | 2022-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $179.63 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.35 | 2024-2025 | Hyqvia |
| Lilly USA, LLC | $151.66 | 2021-2024 | Amyvid, Kisunla |
| Biohaven Pharmaceuticals, INC. | $146.38 | 2021 | |
| Argenx US, INC. | $137.44 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sumitomo Pharma America, INC. | $128.19 | 2023-2024 | Aptiom |
| Mdd US Operations, LLC | $98.08 | 2022-2024 | Gocovri |
| Neurocrine Biosciences, INC. | $83.23 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $72.96 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.65 | 2021-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $71.22 | 2021-2024 | Farxiga, Andexxa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $68.42 | 2025 | |
| Genentech USA, INC. | $65.89 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Neurelis, INC. | $63.75 | 2023-2024 | Valtoco |
| Sk Life Science, INC. | $58.88 | 2021 | |
| Kyowa Kirin, INC. | $58.10 | 2024 | Nourianz |
| Baxter Healthcare | $49.45 | 2023-2024 | Floseal |
| Amgen INC. | $47.33 | 2021-2022 | |
| Si-Bone, INC. | $45.58 | 2023-2024 | |
| Allergan, INC. | $42.45 | 2021 | |
| Ucb, INC. | $42.04 | 2025 | Fintepla |
| Biohaven Pharmaceutical Holding Company LTD. | $35.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $30.96 | 2023-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $28.58 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $27.28 | 2024 | Nuplazid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.81 | 2022-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $19.91 | 2024 | Auvelity |
| Jazz Pharmaceuticals INC. | $15.41 | 2024 | |
| Emd Serono, INC. | $13.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.